Animal & Veterinary
NADA 138-792 MGA; 100/200 Premix, MGA; 500 Liquid Premix, Rumensin;, Tylan; - original approval
Approval Date: August 6, 1990
I. GENERAL INFORMATION
|Sponsor:||The Upjohn Company
|Generic Name:||melengestrol acetate, monensin sodium, tylosin phosphate|
|Trade Name:||MGA; 100/200 Premix, MGA; 500 Liquid Premix, Rumensin;, Tylan;|
|Marketing Status:||Over the Counter (OTC)|
II. INDICATIONS FOR USE
For increased rate of weight gain, improved feed efficiency, suppression of estrus (heat), and reduced incidence of liver abscesses in heifers fed in confinement for slaughter.
A. DOSAGE FORM: Feed
B. ROUTE OF ADMINISTRATION: Oral
C. RECOMMENDED DOSAGES:
- melengestrol acetate
- 0.25 to 0.5 mg/head/day
- monensin sodium 5 to 30 g/ton of air dried complete feed
- tylosin phosphate 8 to 10 g/ton of air dried complete feed (to provide 90 mg/hd/day
NOTES: Approval has been granted to feed 0.25 to 0.5 mg melengestrol acetate (MGA) per head per day in combination with 5 to 30 g monensin per ton of air dried complete feed and 8 to 10 g tylosin per ton of air dried complete feed (to provide 90 mg/hd/day) when each additive is provided via separate supplements or a supplement containing MGA is fed in combination with a complete feed containing monensin and tylosin.
The supplement containing melengestrol acetate provided at a rate of 0.5 to 2.0 pounds per head may be top-dressed onto or mixed with the feed containing monensin and tylosin.
This clearance does not provide for the mixing of melengestrol acetate, monensin and tylosin premixes together in a common supplement or in a complete ration offered for sale by the feed manufacture.
(In compliance with combination approval claims)
The efficacy of melengestrol acetate for increased rate of weight gain, improved feed efficiency and suppression of estrus (heat) in heifers fed in confinement for slaughter is well documented and approved (21 CFR 558.342). Further, the effectiveness of monensin for improved feed efficiency and increased rate of weight gain of feedlot cattle is established and approved (21 CFR 558.311) as is the effectiveness of tylosin for reduction of liver abscesses in the same class of cattle (21 CFR 558.625). For these applications, the efficacy of melengestrol acetate, monensin and tylosin when co-administered was established by conducting a series of field trials under a common protocol. These trials were designed to evaluate the performance of feedlot heifers fed each drug separately and in combination.
A. Pivotal Study
A feedlot heifer study consisting of field trials at nine locations with three replications per location was conducted to generate animal performance data on the combination of melengestrol acetate, monensin and tylosin. Results of each study are reported as well as a summary and statistical analysis of the pooled data from all nine field investigations.
1. Type of Study
a. Clinical (field) trials
2. Investigator names and addresses by location:
*This trial was canceled shortly after it was started for reasons unrelated to the safety and efficacy of the compounds. There were no data generated as a result of this trial.
3. General design of each field investigation
a. Purpose of the field investigation: To evaluate the effect of melengestrol acetate, monensin sodium and tylosin phosphate on the performance of feedlot heifers when fed singly and in combination.
b. Test animals
(1) Species: Bovine Number/group: The number of heifers per treatment group varied from location to location, and ranged from 6 to 14 animals per pen (Table 1).
(2) Subgroup Identity: Heifers used in the field studies were non-pregnant yearlings and the breeds were typical of those commonly found in commercial feedlots. The average initial weights ranged from 674 to 826 pounds (Table 1).
c. Control groups: Groups of heifers fed melengestrol acetate, or monensin or tylosin alone, or monensin and tylosin in combination served as controls. Pairwise, comparisons were made to groups of heifers for the 3 drugs in combination.
d. Diagnosis: Not applicable.
e. Dosage form: (1) Medicated feed: Feed was medicated using melengestrol acetate, monensin or tylosin premixes. Final feeds were prepared using intermediate premixes which were either mixed into or top-dressed onto the bulk of the ration.
f. Route of drug administration: (1) Oral
g. Dosages: The dosages used in the field study were: melengestrol acetate, 0.5 mg/head/day; monensin, 30 gm/ton of air dried feed; tylosin, 10 gm/ton of air dried feed.
h. Days on test: The cattle were fed for a minimum of 90 days, the actual day of trial termination being left up to the investigator's judgement as to when the cattle had reached market weight and condition. The days on test by location are listed on Table 1.
Table 1. General Trial Information
|Location / Trial No.||Number/Pen||Mean Starting Wt/lbs||Days on Test||Estrus Detection (Yes/No)|
|Montana (Huntley) (A) / 540-9665-0-JFM-83-002||12||790||102||Yes|
|Texas / 540-9665-0-JFM-83-003||14||707||104||Yes|
|Michigan / 540-9665-0-JFM-83-004||8||735||97||No|
|Montana (Bozeman) (B) / 540-9665-0-JFM-83-005||8||826||97||Yes|
|Kansas / 540-9665-0-JFM-83-006||6||731||92||No|
|South Dakota / 540-9665-0-JFM-83-007||8||700||126||No|
|Oklahoma / 540-9665-0-JFM-83-008||8||674||112||Yes|
|Washington / 540-9665-0-JFM-93-010||8||773||96||Yes|
|Alabama / 540-9665-0-JFM-001||8||728||99||No|
i. Measurements taken: The following were measured:
Estrus: 2X per day (AM and PM) during days 5 through 47 of the trial. Estrus was measured at five of the nine locations (Table 1).
Cattle weight: Cattle were weighed at about 28 day intervals.
Feed consumption: Daily feed records were maintained.
Daily observations: Individual pens of cattle were observed at least once per day for general activity and physical condition of the cattle.
Liver Evaluation: Individual heifer livers were evaluated for liver abscesses at slaughter.
Performance Data: The treatment by location means for percent standing estrus, average daily gain, feed efficiency and percent abscessed livers are presented in the following tables. While the study included several treatment groups, data from only those pertinent to the subject approval are included.
Table 2. Treatment by Location Means for Percent Standing Estrus
* Huntley, Montana
** Bozeman, Montana
(Eds. note: The following 3 tables consists of 10 columns each.)
Table 3. Treatment by Location Means for Average Daily Gain
Treatment Alabama Oklahoma Kansas Montana* Montana** S Dakota Texas Michigan Washington
melengestrol acetate 2.90 2.18 3.18 2.46 2.89 3.30 3.10 3.45 2.46
tylosin 2.48 2.08 3.03 2.36 2.77 3.04 2.72 3.14 2.16
melengestrol 2.63 2.39 3.17 2.40 2.93 3.19 2.92 3.42 2.52
melengestrol acetate/ 3.01 2.43 2.90 2.73 2.91 3.36 2.72 3.37 2.36
* Bozeman, Montana
** Huntley, Montana
Table 4. Treatment by Location Means for Feed Efficiency
Treatment Alabama Oklahoma Kansas Montana* Montana** S Dakota Texas Michigan Washington
melengestrol acetate 8.30 6.91 8.21 10.06 9.17 6.52 7.28 6.98 8.48
tylosin 8.43 6.81 8.33 10.64 9.35 6.86 7.88 7.41 9.02
melengestrol 8.53 6.25 8.19 10.42 9.03 6.53 7.49 6.85 8.49
melengestrol acetate/ 7.53 5.86 7.90 8.95 8.67 6.37 7.60 6.41 8.40
* Bozeman, Montana
** Huntley, Montana
Table 5. Treatment by Location Means for Percent Abscessed Livers
Treatment Alabama Oklahoma Kansas Montana* Montana** S Dakota Michigan Washington
melengestrol acetate 16.67 16.67 0.00 41.67 14.14 8.33 3.33 16.67
tylosin 0.00 4.17 5.56 12.50 11.11 0.00 0.00 8.33
melengestrol 12.50 0.00 0.00 8.33 11.11 4.17 0.00 8.33
melengestrol acetate/ 4.17 4.17 5.56 16.67 5.56 8.33 0.00 16.67
* Bozeman, Montana
** Huntley, Montana
The results from the 9 individual field investigations were pooled and analyzed statistically to evaluate effectiveness. Average daily gain (ADG) and feed efficiency (FE) data were pooled from all nine locations (Tables 3, 4), estrus suppression data were pooled from five of the nine locations (Table 2) and liver abscess data were pooled from 8 locations (Table 5).
The least squares treatment means pooled across all locations are presented in Table 6.
(Eds. note: The following table consists of 5 columns.)
Table 6. Least Squares Treatment Means Pooled Across Location
% Standing Feed Average % Abscessed
Treatment Estrus*1 Efficiency Daily Gain Livers**1
melengestrol acetate 16.21 7.99 2.88 24.76
tylosin 46.35 8.30 2.64 15.51
melengestrol 23.83 7.97 2.84 16.19
melengestrol 19.17 7.52 2.87 16.13
* Data from five of nine locations
** Data from eight of nine locations
1 % Standing Estrus and % Abscessed Livers means are based on Freeman-Tukey
5. Statistical Analysis:
A least squares analysis of variance for the transformed liver abscess and performance data from the nine locations,and transformed estrus data from 5 locations was conducted. The results of this analysis are presented on Table 7.
(Eds. note: The following table consists of x columns.)
Table 7. The significance levels for the comparisons required for the combinations were:
Combination Comparison Estrus FD ADG Abscess
MGA + Monensin(M) + T MGA + T vs MGA + M + T .00015
T vs MGA + M + T .0000003 .00010
MGA vs MGA + M + T .00752
The combination of melengestrol acetate, monensin and tylosin was justified. In the melengestrol acetate + tylosin vs. melengestrol acetate + monensin + tylosin contrast, the contribution of monensin for increased feed efficiency (P = 0.00015) was demonstrated. In the tylosin vs. melengestrol acetate, tylosin, and monensin contrast, the estrus suppression effect of melengestrol acetate was demonstrated (P = 0.0000003) as was the average daily gain contribution of melengestrol acetate and monensin (P = 0.00010). The contribution of tylosin for control of liver abscesses (P = 0.00752) was evident in the melengestrol acetate vs. melengestrol acetate, monensin and tylosin contrast (Table 7).
The data generated by the nine location field study demonstrated that the melengestrol acetate, monensin, tylosin combination is justified for it's effect on estrus suppression, improved feed efficiency, increased average daily gain and reduction of liver abscesses.
7. Adverse Reactions
No adverse reactions due to the feeding of melengestrol acetate, monensin, or tylosin, either singly or in combination were reported.
8. Special Issues
Compliance with combination drug policy:
a. The effectiveness and safety of melengestrol acetate, monensin, and tylosin when fed singly to feedlot cattle are well documented in their respective approved NADAs. The results of adequately controlled studies were submitted to the FDA in support of these respective NADAs. Such data resulted in the approval of melengestrol acetate as per CFR 558.342, monensin as per CFR 558.355 and tylosin as per CFR 558.625. Data generated in support of combination usage have demonstrated that melengestrol acetate, monensin and tylosin fed together are effective and safe.
The data support compliance with 21 CFR 514.1(b)(8)(v) and CVM's combination drug guidelines (November 9, 1983). The combination is justified as detailed in sections 4, 5 and 6 of this application.
The use of untreated controls was not deemed necessary as a test for general effectiveness because the individual drugs have been previously shown to be effective and already approved at the levels tested. The treatment groups consisting of the individual drugs and the two-way combinations served as the appropriate controls for the respective two-way combination. Thus, these treatment groups essentially served as negative controls with respect to 21 CFR 514.111(a)(5)(ii)(a)(4), an the studies were properly controlled.
To justify the combination, comparisons were made which demonstrated that each drug made a statistically significant contribution to the combination. The three-way combination provides a benefit that cannot be obtained from any of the possible two-way combinations.
A comparison of melengestrol acetate vs melengestrol acetate-monensin-tylosin for transformed percent liver abscesses demonstrates the contribution of tylosin to the combination. This comparison is based on the the fact that neither melengestrol acetate nor monensin has an effect on liver abscesses. Data in the monensin-tylosin NADA (104-646) verify the assumption that monensin has no effect on liver abscesses and data in NADA (138-995) verify that melengestrol acetate has no effect on liver abscesses.
A comparison of tylosin vs melengestrol acetate-monensin-tylosin addresses melengestrol acetate's contribution to the combination. Since melengestrol acetate has estrus suppression activity and monensin does not, this comparison is a valid measure of the effect of melengestrol acetate in the combination. This assumption is verified by data in NADA 124-309 (melengestrol acetate-monensin).
A comparison of melengestrol acetate-tylosin vs melengestrol acetate-monensin-tylosin addresses monensin's contributions that significantly improved feed efficiency is available with the three-way combination when compared to the two-way, melengestrol acetate-tylosin.
The proposed ranges for each drug are justified when fed in combination since the highest levels proposed were tested in combination for efficiency and human and animal safety.
B. Corroborative studies: N/A
V. ANIMAL SAFETY
A. Pivotal study
The safety of melengestrol acetate, monensin, and tylosin in the bovine have been documented as evidenced by their respective approvals (21 CFR 558.342 for melengestrol acetate, 21 CFR 558.355 for monensin, and 21 CFR 558.625 for tylosin) as feed additives. The following pivotal study was conducted to establish the target animal safety of these three additives when fed in combination.
1. A 90 day, subchronic study was conducted.
A.D. Hall, Ph.D., D.V.M.
The Upjohn Company
Kalamazoo, MI 49001
3. General Study design:
a. Purpose: The purpose of this study was to evaluate the safety of the melengestrol acetate, monensin and tylosin when fed in combination in the diet of yearling heifers at 1 to 5 times the recommended dosages.
b. Test animals:
1) Species: Bovine Number per Group: 14 control, 7 treated.
2) Breed: Hereford
Sex: Female (heifers)
Weight: 284 to 378 kg initial weight
c. Dosage form:
1) Drug premixes were incorporated in the feed through the use of intermediate premixes.
2) Formulations were typical of those used in commercial feedlot.
d. Dosage used:
1) Control: No drugs
0.5 mg melengestrol acetate per head per day
30 g monensin sodium per ton of air dried feed
10 g tylosin phosphate per ton of air dried feed
1.5 mg melengestrol acetate per head per day
90 g monensin sodium per ton of air dried feed
30 g tylosin phosphate per ton of air dried feed
2.5 mg melengestrol acetate per head per day
150 g monensin sodium per ton of air dried feed
50 g tylosin phosphate per ton of air dried feed
e. Routes of administration: Oral
f. Test duration: 90 days
g. Parameters measured:
1) Clinical observations included twice daily health checks, daily observations, body weight, daily feed consumption.
2) Clinical pathology
The following hematology parameters were measured:
- Total leukocyte count
- Total erythrocyte count
- Mean corpuscular volume
- Mean corpuscular hemoglobin
- Mean corpuscular hemoglobin concentration
Microscopic Examination: WBC differential
The following serum chemistry parameters were measured:
- Aspartate aminotransferase
- Alkaline phosphatase
- Inorganic Phosphorus
- Blood Urea Nitrogen
- Total Bilirubin
- Total Protein
- Creatinine phosphokinase
- Sorbitol dehydrogenase
Urine specimens were collected via paracentesis from the urinary bladder at the time of necropsy. The following parameters were measured:
Microscopic Examination: Formed elements
3) Gross and microscopic pathology:
The following is a list of organs and tissues that were examined grossly and had a representative sample fixed in 10% neutral buffered formalin for microscopic evaluation:
Mammary gland Ileum
Mediastinal lymph node Cecum
Mesenteric lymph node Colon
Lung Heart (one section from each atrium and ventricle)
Liver Gall bladder
Kidneys Aorta (and small arteries)
Urinary bladder Bone
Spleen Bone Marrow (smear)*
*Bone marrow smears were made at the time of necropsy, air dried and fixed for 30 seconds or more in methanol. Slides were stained with Wrights stain.
The following organs were weighed at necropsy, paired organs weighed together:
Adrenals, liver, kidneys and heart.
a. Clinical Observation: No adverse, drug-related clinical signs were observed during this study. Although there were no significant differences in average daily gain (ADG) between treated and control animals at mid-study and at termination, there was a trend toward decreased ADG at the 3X and 5X levels of treatment.
b. Clinical pathology: Occasional statistically significant changes in several hematologic and serum chemistry parameters were detected, but all values were well within normal acceptable ranges and no dose-related trends were seen.
c. Gross and microscopic pathology: Several gross and histologic tissue changes were observed, but due to the relative even distribution of the changes in all dose groups including controls, these findings were considered to be incidental rather than drug-related.
a. Based upon the results of this study, the combination of melengestrol acetate, monensin and tylosin phosphate in the daily feed of yearling heifers appears to be non-toxic when fed for 90 days at up to 5 times the recommended dose.
VI. HUMAN SAFETY:
A. Drugs for use in food animals
1. Toxicity tests
Data regarding toxicity testing in melengestrol acetate, monensin sodium and tylosin phosphate are contained in the approved NADAs for the three above mentioned compounds.
2. Safe concentration of residues
Tolerances for melengestrol acetate, monensin sodium and tylosin phosphate are published in the Code of Federal Regulations. Melengestrol acetate is currently approved under 21 CFR 558.342 for use in heifers at 0.25 to 0.50 mg/head/day with a 48-hour withdrawal period. No residues of melengestrol acetate may be found in uncooked edible tissues of cattle with a method sensitive to 25 ppb (21 CFR 556.380). The tolerance for monensin in edible tissue of cattle under 21 CFR 556.347 is 0.7 ppm with no withdrawal period established for cattle under 21 CFR 558.311. The tolerance for tylosin phosphate has been established at 0.2 ppm (negligible residue) in uncooked fat, muscle, liver and kidney (CFR 556.740). Tylosin phosphate has no withdrawal period established under 21 CFR 558.625.
3. Metabolism and total residue depletion studies
Numerous studies have been conducted relative to the metabolism and depletion of residues of melengestrol acetate, monensin, and tylosin when administered individually to cattle. The results of those studies have been filed under the following submissions:
(Eds. note: The following table consists of 3 columns.)
Melengestrol Acetate monensin sodium tylosin phosphate
NADA 34-254 NADA 38-878 NADA 12-491
NADA 39-402 NADA 95-735 NADA 104-646
4. Residue depletion noninterference study
The following study was conducted to support the use of the three-way combination of melengestrol acetate, monensin sodium and tylosin phosphate in heifers:
Sponsor: The Upjohn Company
L.F. Krzeminski, Ph.D.
The Upjohn Company
P. R. Handy, Ph.D.
Lilly Research Laboratories
Greenfield, IN 46140
Groups of feedlot heifers were fed for 90 days with the drug combinations and treatment levels described below.
(Eds. note: The following table consists of 4 columns.)
Number of Treatment
Group Animals Level Treatment*
1 14 0 Control
2 7 1X 0.5 mg MGA + 30 g monensin + 10 g
3 7 3X 1.5 mg MGA + 90 g monensin + 30 g
4 7 5X 2.5 mg MGA + 150 g monensin + 50 g
* Melengestrol acetate treatment expressed as mg/head/day, monensin and
tylosin expressed as gram/ton air-dried ration.
The animals in each group were slaughtered within 16 hours following their last feeding. Perirenal fat was collected from all four treatment groups for the melengestrol acetate analysis, and liver samples were collected from the group 1 and 2 animals for the assay of monensin and tylosin.
a. Residues of melengestrol acetate: The samples of pererenal fat from each animal were assayed for residues of melengestrol acetate using the official AOAC gas chromatographic method. Analysis of the samples from the group 2 (1X) animals showed that all fat samples were below the 25 ppb tolerance for MGA and five of the seven samples were below the 10 ppb limit of reliable measurement of the assay. The two fat samples that gave positive responses had MGA levels of 12.7 and 13.7 ppb.
Fat samples from groups 3 and 4 (the heifers dosed at 3X and 5X levels) yielded average residue levels of 37.6 and 49.4 ppm, respectively.
b. Residues of monensin: Liver tissue that was collected from the seven control animals and the seven heifers fed the group 2 (1X) ration were assayed for monensin by a method that measures microbiologically active residues of the drug. No positive responses in any of the samples were obtained by this method which has a limit of quantitation of 0.04 ppm.
c. Residues of tylosin: The liver tissue samples from the group 2 (1X) heifers and seven of the control animals were assayed for tylosin by the official assay which measures microbiologically active residues of the drug. No positive responses were obtained for any of the samples by this method which has a limit of quantitation of 0.1 ppm.
5. Assay noninterference data
a. Melengestrol acetate assay: Data were generated using spiked control fat tissue samples to demonstrate that the presence of tylosin and monensin does not interfere with the assay of MGA. The study was also intended to show that MGA is stable in frozen fat tissue over a period of 60 days.
Samples of freshly ground control bovine fat tissue were spiked with MGA, tylosin and monensin at the following levels:
monensin sodium: 5.0 ppm
Tylosin phosphate: 1.0 ppm
The spiked samples were assayed in duplicate for MGA by the official AOAC method after 0, 15, 30, 45, and 60 days of storage at -20°C. The average recoveries are shown below.
(Eds. note: The following table consists of 8 columns.)
--------Day of Assay---------
0 15 30 45 60 Ave. S.D.
Percent Recovery 93 88 109 101 98 98 8.0
b. Monensin assay: The data to demonstrate that the presence of tylosin and MGA does not interfere with the assay of monensin in cattle liver are contained in study S-AAC-84-02 conducted by Elanco Products Company. In that study, samples of liver tissue from control heifers were composited and fortified with 0.06 ppm monensin, 0.2 ppm tylosin and 0.2 ppm MGA. The analysis of those samples by the thin-layer bioautographic method for monensin showed no interference by tylosin and MGA.
The stability of monensin in frozen liver tissue was demonstrated through the use of fortified control samples. Liver tissue from control animals was spiked with monensin at 0.06 ppm, frozen for 26 days, and then assayed for monensin. Recoveries averaged 104% of the theoretical spike.
c. Tylosin assay: Data to demonstrate that the presence of MGA and monensin does not interfere with the assay of tylosin were generated by Elanco Products Company in study S-AAC-84-02. Samples of liver from control heifers were composited and fortified with 0.2 ppm MGA, 0.2 ppm monensin, and 0.2 ppm tylosin. The samples were assayed for tylosin by the cylinder plate microbiological method using Micrococcus luteus as the test organism. No interference was detected by the presence of monensin and MGA.
The stability of tylosin in frozen liver tissues was demonstrated in study MRC8910 conducted by the Elanco Products Company. Liver tissue from control animals was fortified with 0.2 ppm tylosin and then frozen. Portions of the samples were thawed at intervals up to 56 days and assayed for tylosin. The stability of tylosin through 56 days was indicated by the recoveries in the following table:
(Eds. note: The following table consists of 3 columns.)
Tylosin Storage Stability in Frozen Liver
Storage Mean Tylosin Percent
(days) Recovery (ppm) Theorectical
0 0.166 83%
14 0.239 114%
28 0.172 86%
56 0.162 81%
Regression analysis of these data demonstrates satisfactory tylosin stability for the period the tissues in the residue depletion study were stored before assay.
The residue depletion and assay noninterference studies presented above demonstrate that the combined feeding of melengestrol acetate, monensin sodium, and tylosin phosphate at their highest approved levels results in tissue residues below the tolerance levels for each of the three drugs at 16 hours of withdrawal. The data also show that each drug in the three-way combination does not interfere with the assays for the others. This work confirms the adequacy of the 48 hour withdrawal time required for the presence of MGA in the combination and demonstrates that the use of these feed additives in combination does not pose a hazard to public health.
6. Regulatory methods
Practical analytical methods of analysis for tissue residues of melengestrol acetate, monensin sodium and tylosin phosphate may be found in the Food Additives Analytical Manual on display in FDA's Freedom of Information Public Room (Room 12-A-30), 5600 Fishers Lane, Rockville, MD 20857.
VII. AGENCY CONCLUSIONS
These NADAs provide for the combination use of MGA, monensin sodium, and tylosin phosphate at the levels of 0.25 to 0.5 mg/head/day, 5 to 30 g/ton of feed, and 8 to 10 g/ton of feed (to supply 90 mg/head/day), respectively; for increased rate of weight gain, improved feed efficiency, suppression of estrus (heat), and reduced incidence of liver abscesses in heifers fed in confinement for slaughter. Adequate data were submitted which show that the MGA, monensin, tylosin combination is justified for its effects on estrus suppression, improved feed efficiency, increased rate of weight gain, and reduction of liver abscesses. Each drug; MGA, monensin, and tylosin has been shown to make a significant (P < .05) contribution to the effectiveness of the combination. The combination, when fed at up to 5X the highest recommended combination approval (0.5 mg MGA/head/day plus 30 g monensin/ton, and 10 g tylosin phosphate/ton for 90 days), did not produce an adverse effect. No changes were made in the approved levels of the compounds or in the target animal and the non-interference of tylosin phosphate, monensin sodium, and MGA with the analytical methods for MGA, monensin and tylosin phosphate, respectively, was demonstrated. Accordingly, approval of theses NADAs is not expected to increase human exposure to drug residues, and therefore did not require a complete re-evaluation of the human safety data in the original applications. For the purposes of human food safety review, these original NADAs have been treated as Category II supplements under the Agency's Supplemental Policy (42 FR 64367). These production drugs are OTC because they do not raise any special safety concerns.
VIII. LABELING (Attached)
- Type C Medicated Feed package label and mixing instructions
- Type C Medicated Feed Liquid supplement package label and mixing instructions
Copies of these labels may be obtained by writing to the:
Food and Drug Administration
Freedom of Information Staff (HFI-35)
5600 Fishers Lane
Rockville, MD 20855
Or requests may be sent via fax to: (301) 443-1726. If there are problems sending a fax, call (301) 443-2414.